Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Journeytcon Aug 24, 2024 7:40pm
145 Views
Post# 36194916

RE:Finally a Phase III trial...

RE:Finally a Phase III trial...Great news and just as i predicted and blogged.   Take breast cancer trial through the back door.  Screw the FDA and Pfizer. They made sure Pela would fail!   They didnt want a cure they couldnt profit from.  FDA advisory limiting population to those dropping out of the first ADV treatment effectively crushes market potential.  And the breast cancer trial lost 50% of the best responders because primary investigators didnt administer Tylenol.    I was hard on ONC for not writing this into the treatment protocol.   But truth is ONC was getting into bed with a viper and didnt know it.   
By recent example, Pfizer et al killed Ivermectin off label use to treat COVID.   If Ivermectin deployed as effective, pharma would never by law garnered liability protection for the covi-vax.   Ivermectin is highly effective and dirt cheap treating covid.  
<< Previous
Bullboard Posts
Next >>